CD274 and breast cancer: The surrogate-imaging agent, 111In-DTPA-anti-PD-L1-BC, allowed us to gauge the impact of the Ab protein concentration on the distribution of these agents, helping to select an optimal concentration to evaluate the targeted alpha-particle therapy agent, 225Ac-DOTA-anti-PD-L1-BC.